36291220|t|Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review.
36291220|a|Pimavanserin (PMV) is the first approved drug for treating hallucinations and delusions in Parkinson's disease (PD) psychosis. Psychosis is one of the leading causes of nursing home placement in people with PD. Furthermore, hallucinations are a more frequent cause of institutionalization than motor disability or dementia related to PD. The management of PD psychosis involves antipsychotic medications. Most of the drugs in this class directly block dopamine D2 receptors, leading to significantly worsening motor symptoms in patients with PD. The most commonly used medications for managing PD psychosis are quetiapine, clozapine, and PMV. This literature review aims to study pimavanserin's history, mechanism, clinical trials, and post-marketing experience. PMV is a potent 5-HT2A receptor antagonist/inverse agonist. Moreover, this drug can interact with 5-HT2C receptors. We calculated some physicochemical descriptors and pharmacokinetic properties of PMV. Eight clinical trials of PMV and PD psychosis are registered on ClinicalTrials.gov. Only four of them have complete results already published. Meta-analytic results showed that PMV efficacy is inferior to clozapine. However, PMV has a significantly lower number of side-effects for managing psychosis in PD. Medicare database assessment revealed 35% lower mortality with PMV compared to other atypical antipsychotics. Moreover, sensitive statistical analysis demonstrated that PMV is a protective factor for the risk of falls in individuals with PD.
36291220	0	12	Pimavanserin	Chemical	MESH:C510793
36291220	17	36	Parkinson's Disease	Disease	MESH:D010300
36291220	37	46	Psychosis	Disease	MESH:D011618
36291220	68	80	Pimavanserin	Chemical	MESH:C510793
36291220	82	85	PMV	Chemical	MESH:C510793
36291220	127	141	hallucinations	Disease	MESH:D006212
36291220	146	155	delusions	Disease	MESH:D063726
36291220	159	178	Parkinson's disease	Disease	MESH:D010300
36291220	180	182	PD	Disease	MESH:D010300
36291220	184	193	psychosis	Disease	MESH:D011618
36291220	195	204	Psychosis	Disease	MESH:D011618
36291220	275	277	PD	Disease	MESH:D010300
36291220	292	306	hallucinations	Disease	MESH:D006212
36291220	362	378	motor disability	Disease	MESH:D009069
36291220	382	390	dementia	Disease	MESH:D003704
36291220	402	404	PD	Disease	MESH:D010300
36291220	424	436	PD psychosis	Disease	MESH:D010300
36291220	596	604	patients	Species	9606
36291220	610	612	PD	Disease	MESH:D010300
36291220	662	674	PD psychosis	Disease	MESH:D010300
36291220	679	689	quetiapine	Chemical	MESH:D000069348
36291220	691	700	clozapine	Chemical	MESH:D003024
36291220	706	709	PMV	Chemical	MESH:C510793
36291220	748	760	pimavanserin	Chemical	MESH:C510793
36291220	831	834	PMV	Chemical	MESH:C510793
36291220	847	862	5-HT2A receptor	Gene	3356
36291220	1028	1031	PMV	Chemical	MESH:C510793
36291220	1058	1061	PMV	Chemical	MESH:C510793
36291220	1066	1078	PD psychosis	Disease	MESH:D010300
36291220	1210	1213	PMV	Chemical	MESH:C510793
36291220	1238	1247	clozapine	Chemical	MESH:D003024
36291220	1258	1261	PMV	Chemical	MESH:C510793
36291220	1324	1333	psychosis	Disease	MESH:D011618
36291220	1337	1339	PD	Disease	MESH:D010300
36291220	1404	1407	PMV	Chemical	MESH:C510793
36291220	1510	1513	PMV	Chemical	MESH:C510793
36291220	1553	1558	falls	Disease	MESH:C537863
36291220	1579	1581	PD	Disease	MESH:D010300
36291220	Negative_Correlation	MESH:D003024	MESH:D010300
36291220	Negative_Correlation	MESH:C510793	MESH:D006212
36291220	Negative_Correlation	MESH:C510793	MESH:D011618
36291220	Negative_Correlation	MESH:C510793	MESH:D010300
36291220	Comparison	MESH:C510793	MESH:D003024
36291220	Negative_Correlation	MESH:C510793	MESH:C537863
36291220	Negative_Correlation	MESH:C510793	3356
36291220	Negative_Correlation	MESH:C510793	MESH:D063726
36291220	Negative_Correlation	MESH:D000069348	MESH:D010300

